Ethacrynic Acid Enhances the Antitumor Effects of Afatinib in EGFR/T790M-Mutated NSCLC by Inhibiting WNT/Beta-Catenin Pathway Activation

Figure 1

The validation of cytotoxic effects of afatinib and EA in NSCLC cells. (a) Interaction between afatinib or ethacrynic acid and glutathione. (b–e) The cell proliferation of A549 or H1975 cells after treatment with afatinib or EA at different time points. (f–i) IC50 value of afatinib or ethacrynic acid in different cells at 48 h. The IC50 value is the mean concentration of drug that reduced cell survival by 50%.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)